<DOC>
	<DOCNO>NCT00003500</DOCNO>
	<brief_summary>RATIONALE : Antineoplastons naturally-occurring substance may also make laboratory . Antineoplastons may inhibit growth cancer cell . PURPOSE : This phase II trial study effectiveness antineoplaston therapy treat patient refractory recurrent intermediate-grade stage II , stage III , stage IV non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Antineoplaston Therapy Treating Patients With Refractory Recurrent Intermediate-Grade Stage II , Stage III , Stage IV Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety possible effectiveness antineoplastons A10 AS2-1 patient serious immediately life threaten refractory recurrent intermediate grade non-Hodgkin 's lymphoma . - Describe response , tolerance , side effect regimen patient . OUTLINE : This open-label study . Patients receive gradually escalate dos antineoplaston A10 antineoplaston AS2-1 intravenous injection 6 time daily maximum tolerate dose reach . Treatment continue 12 month absence disease progression unacceptable toxicity . Patients achieve complete response , partial response , stable disease continue treatment . Tumors measure least every 8 week 6 month , every 3 month 1.5 year , every 6 month 2 year , annually 2 year . Patients follow survival . PROJECTED ACCRUAL : A total 20-40 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage II , III , IV intermediategrade nonHodgkin 's lymphoma respond relapsed standard primary chemotherapy regimen plus least 1 standard secondline salvage chemotherapy regimen NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 2 month Hematopoietic : WBC great 2000/mm^3 Platelet count great 50,000/mm^3 Hepatic : Bilirubin great 2.5 mg/dL Renal : Creatinine great 2.5 mg/dL No history renal condition contraindicate high dosage sodium Cardiovascular : No uncontrolled hypertension No history congestive heart failure No history cardiovascular condition contraindicate high dosage sodium Other : Not pregnant nursing Fertile patient must use effective contraception 4 week study participation No serious infection require treatment PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover No concurrent immunomodulatory agent ( e.g. , interferon interleukin2 ) Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) recover No concurrent antineoplastic agent Endocrine therapy : At least 4 week since prior dexamethasone , prednisone , corticosteroids No concurrent corticosteroid Radiotherapy : At least 8 week since prior radiotherapy recover Surgery : Not specify Other : Prior cytodifferentiation therapy allow No prior antineoplaston therapy No concurrent antibiotic , antifungal , antiviral</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
</DOC>